Neisseria gonorrhoea continues to show high levels of resistance to azithromycin across the European Union and European Economic Area, according to the 2016 results of the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP).
This report describes the second molecular typing survey of N. gonorrhoeae across the EU/EEA and provides recent information on NG-MAST STs/Gs and genotypes based on WGS circulating in 21 EU/EEA Member States.
Can whole genome sequencing illustrate changes in drug susceptibility of gonorrhoea to antimicrobials used for treatment and so help to define more effective treatment regimens?
Within a matter of weeks, three cases of gonorrhoea that are resistant to the recommended first line antibiotic treatment have been detected in Europe and Australia. These are the first global reports of Neisseria gonorrhoeae with high-level resistance to azithromycin and ceftriaxone resistance that also show resistance to several other vital antibiotics. At a time with limited alternatives to the current dual therapy, lack of a vaccine and insufficient surveillance capacity in some regions, these cases highlight the growing threat of drug-resistance – which could lead to untreatable gonorrhoea.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 22-28 April 2018 and includes updates on dengue, chikungunya, seasonal influenza, yellow fever, gonorrhoea and cholera.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 25-31 March 2018 and includes updates on dengue, chikungunya, measles, listeria, Borna diseases and gonorrhoeae.